FindTrial
Sign In

Evaluation of Siddha herbal formulation, Vipro, in the management of uncomplicated respiratory infections

A single centre, prospective, randomized, open labelled clinical study to evaluate the effectiveness of Siddha herbal formulation, Vipro, in uncomplicated respiratory infections

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025559
Enrollment
60
Registered
2020-06-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J00- Acute nasopharyngitis [common cold] Health Condition 2: J029- Acute pharyngitis, unspecified Health Condition 3: J069- Acute upper respiratory infection,unspecified Health Condition 4: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Siddha herbal formulation, Vipro: The traditional medicinal ingredients of the product processed with essential oil from Cocus nucifera L, as base have been scientifically proven to war

Sponsors

Buy Happy Marketing LLP
Lead Sponsor
Qscience Therapeutics
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Having uncomplicated respiratory infections, at least for less than 5 days, diagnosed with clinical symptoms and signs of fever, myalgia, rhinitis, sore throat, throat pain, cough, expectoration and head ache 2. Consenting to participate in the study and sign the informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with uncontrolled co-morbid conditions like Diabetes mellitus, Hypertension and Bronchial asthma 2. Patients with Lower respiratory tract infections, Chronic Bronchitis, Chronic obstructive air way problems 3. Patients with significant Cardiovascular, Neurological , Psychiatric, Gastro intestinal and other system infections or disorders and malignancies 4. Hypersensitivity to the herbal ingredients in the formulations and other medications prescribed in the study 5. Pregnant and feeding mothers 6. When the patients are interviewed for selection, all those patients who come under the testing criteria for COVID-19 as per ICMR guidelines will be tested for COVID â?? 19 and if they are found to be positive, they will be excluded from participating in the study.

Design outcomes

Primary

MeasureTime frame
1. Reducing the severity of clinical symptoms such as fever, myalgia, rhinitis, sore throat, throat pain, cough, expectoration and head acheTimepoint: Daily for 7 days—

Secondary

MeasureTime frame
1. Reducing the worsening of clinical symptoms 2. Reducing the complicationsTimepoint: Daily for 7 days—

Countries

India

Contacts

Public ContactDr R Arunkumar

Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education

arunkumarr@chettinadhealthcity.com9884212644

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026